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G-CSF stimulates mobilization of hematopoietic pro-
genitor cells (HPCs) from bone marrow by disrupting
the CXCR4/SDF-1a retention axis. We show here
that distinct factors and mechanisms regulate the
mobilization of endothelial (EPCs) and stromal pro-
genitor cells (SPCs). Pretreatment of mice with
VEGF did not disrupt the CXCR4/SDF-1a chemokine
axis but stimulated entry of HPCs into the cell cycle
via VEGFR1, reducing their migratory capacity
in vitro and suppressing their mobilization in vivo.
In contrast, VEGF pretreatment enhanced EPCmobi-
lization via VEGFR2 in response to CXCR4 antago-
nism. Furthermore, SPC mobilization was detected
when the CXCR4 antagonist was administered to
mice pretreated with VEGF, but not G-CSF. Thus,
differential mobilization of progenitor cell subsets is
dependent upon the cytokine milieu that regulates
cell retention and proliferation. These findings may
inform studies investigating mechanisms that regu-
late progenitor cell recruitment in disease and can
be exploited to provide efficacious stem cell therapy
for tissue regeneration.
INTRODUCTION
The bone marrow is a reservoir of progenitor cells, including
hematopoietic progenitor cells (HPCs), fibrocytes, mesenchymal
stem cells (MSCs), and endothelial progenitor cells (EPCs). In
response to disease or tissue injury, these cells are mobilized
from the bonemarrow and recruited into tissues where they con-
tribute either to disease progression or tissue repair (Takahashi
et al., 1999; Orlic et al., 2001; Rankin, 2008). EPCs recruited
into ischemic tissues promote angiogenesis and thereby contrib-
ute to tissue regeneration (Asahara et al., 1997; Takahashi et al.,
1999; Nolan et al., 2007). MSCs have the capacity to differentiate
into adipocytic, chondrocytic, and osteogenic lineages and po-
tentially other lineages including epithelial, myocardial, or neuro-
nal lineages (Pittenger et al., 1999). It is thought, therefore, that
MSCs may be used therapeutically to promote tissue regenera-
tion in the treatment of diseases such asosteogenesis imperfecta
andParkinson’sdisease (HessandBorlongan, 2008;Bielby et al.,
2007). Additionally, MSCs have been reported to have immuno-
suppressive properties, and as such, theymay be therapeutically
useful for the treatment of autoimmune diseases (Le Blanc and62 Cell Stem Cell 4, 62–72, January 9, 2009 ª2009 Elsevier Inc.Ringden, 2007). The therapeutic application of these distinct
subpopulations of stem cells in the context of specific diseases
is, therefore, widely anticipated. Currently, however, there are
both practical and technical complications associated with
harvesting, isolation, ex vivo expansion, and delivery of these
cells. An alternative strategy for stem cell therapy is to stimulate
the mobilization of stem cells from the bone marrow into the
circulation, thereby circumventing these issues. This approach
has been established clinically using G-CSF to mobilize HPCs
for bone marrow transplants (BMTs) (Cashen et al., 2004).
Mobilization of progenitor cells is a multistage process, with
initial release from their bone marrow niche followed by active
migration across the bone marrow sinusoidal endothelium. The
chemokine axis SDF-1a/CXCR4 is critically involved in the reten-
tion of hematopoietic stem cells within the bone marrow (Lev-
esque et al., 2003). At a molecular level, G-CSF has been shown
to act by disrupting the SDF-1a/CXCR4 retention axis, both by
reducing CXCR4 expression on HPCs and levels of SDF-1a in
the bone marrow (Levesque et al., 2003). This knowledge has
led to the development of CXCR4 antagonists as HPC-mobiliz-
ing agents. In contrast to G-CSF, such antagonists work acutely,
mobilizing HPCs within an hour. Moreover, we and others have
shown that chronic G-CSF therapy combined with acute admin-
istration of a CXCR4 antagonist synergistically enhances HPC
mobilization from the bonemarrow (Broxmeyer et al., 2005; Mar-
tin et al., 2006). This combination therapy has recently shown
greater efficacy compared to G-CSF alone in phase III clinical
trials for BMT (Calandra et al., 2008). While it has been shown
that administration of a CXCR4 antagonist alone increases the
circulating numbers of EPCs and improves tissue perfusion fol-
lowing ischemia in animals (Capoccia et al., 2006; Shepherd
et al., 2006), it is not known whether G-CSF therapy in combina-
tion with acute administration of the CXCR4 antagonist acts
synergistically to mobilize EPCs.
In addition to factors that disrupt the retention of EPCs in the
bone marrow, EPCs may also be mobilized by factors, such as
VEGF, that stimulate their migration (Asahara et al., 1997); how-
ever, the relative efficacy of VEGF versusG-CSF alone or in com-
bination with other mobilizing reagents has not been specifically
assessed with respect to EPC mobilization. There is evidence
that bone-marrow-derived MSCs contribute to tissue regenera-
tion, suggesting that these cells are alsomobilized in response to
tissue injury; however, the factors and mechanisms regulating
the mobilization of MSCs are currently unknown.
We have previously shown that different subpopulations of
leukocytes are selectively mobilized from the bone marrow in
response to specific blood-borne mediators via distinct mecha-
nisms (Palframan et al., 1998; Martin et al., 2003; Wengner et al.,
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differential mobilization of discrete populations of progenitor
cells.
RESULTS
The CXCR4 Antagonist Mobilizes Discrete Populations
of Progenitor Cells in Mice Pretreated with G-CSF
or VEGF
Circulating numbers of HPCs, EPCs, and SPCs were determined
1 hour after the administration of the CXCR4 antagonist,
AMD3100, to mice pretreated over 4 days with G-CSF, VEGF,
or vehicle control. Administration of the CXCR4 antagonist alone
increased circulating numbers of HPCs and EPCswithin 1 hr (Fig-
ures 1B and 1C). Interestingly, SPCs were not detected in the
blood. G-CSF pretreatment of mice also increased circulating
numbers of HPCs and, to a lesser extent, EPCs. (Figures 1B
and 1C). Intriguingly, no SPCs were detected (Figure 1D). While
G-CSF pretreatment followed by acute administration of the
Figure 1. G-CSF and VEGF Pretreatment
Differentially Regulate Circulation of Pro-
genitor Cells in Response to a CXCR4
Antagonist
(A) Experimental protocol. Mice were pretreated
with G-CSF, VEGF, or vehicle (PBS) once daily
for 4 days (100 mg/kg i.p.). Twenty-four hours after
the last injection, mice were administered a
CXCR4 antagonist (AMD3100 5 mg/kg i.p, closed
bars) or vehicle (PBS, open bars). Sixty minutes
later, blood was taken for analysis of circulating
(B) CFU-HPC, (C) CFU-EPC, and (D), CFU-SPC.
CFU-HPC, CFU-EPC, and CFU-SPC are shown
as number of colonies per ml blood. n = 5–8
mice per group. Data are means ± SEM. *p <
0.05, **p < 0.01, and ***p < 0.001 between
selected groups.
CXCR4 antagonist synergistically en-
hanced circulating numbers of HPCs
(Figure 1B), no such synergism (or even
additive effect) was apparent for EPCmo-
bilization (Figure 1C). Furthermore, SPCs
could not be detected. Of note, EPCs
were scored after 21 days in culture and
were shown to be CD34-, VEGFR2-,
VE-Cadherin-, and vWF-positive (Figures
S1, S2, and S3 available online). Further-
more, these EPCs stained positively with
GS-lectin, tookupacetyl-LDL, and formed
tubules invitro.TheseEPCsare, therefore,
equivalent to the so-called ‘‘late out-
growth EPCs’’ that have the capacity to
form vessels in vivo (Yoder et al., 2007;
Nolan et al., 2007). Importantly, the mobi-
lized EPCs did not express CD115, CD14,
or CD45 and are, thus, distinct from both
HPCs and the EPCs that are of monocytic
origin (Figures S1, S2, and S3) (Yoder
et al., 2007; Nolan et al., 2007).
VEGF administration can increase circulating number of cells
with an EPC phenotype (Asahara et al., 1997). Similarly, we ob-
served an increase in EPC numbers following VEGF treatment
of mice over 4 days (Figure 1C). Moreover, a more than additive
increase in EPC numbers was observed when the CXCR4 antag-
onist was administered acutely to mice pretreated with VEGF as
compared to mice treated with VEGF alone or administered a
CXCR4 antagonist alone (p < 0.05; Figure 1C). In contrast to
G-CSF, VEGF treatment did not increase circulating numbers
of HPCs (Figure 1B). Further, we unexpectedly found that
VEGF pretreatment profoundly suppressed circulating numbers
of HPCs (77% reduction) mobilized by the CXCR4 antagonist
(p < 0.01, Figure 1B). Uniquely, VEGF treatment combined with
the CXCR4 antagonist led to a significant increase in circulating
SPCs (CFU-F p < 0.001; Figure 1D). Mobilized SPCs displayed
the same antigen expression as bone-marrow-derived SPCs
(Figure S4A), which on expansion, exhibited trilineage differenti-
ation potential (Figures S4C–S4E). Mobilized SPCs were plastic-
adherent cells, shown to be CD29 and CD105 positive yet CD34Cell Stem Cell 4, 62–72, January 9, 2009 ª2009 Elsevier Inc. 63
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characteristics as murine mesenchymal stem cells (Phinney
et al., 1999; Pittenger et al., 1999; Meirelles and Nardi, 2003).
Mobilized SPCs were also negative for VE-Cadherin and vWF
and were, therefore, distinct from mobilized EPCs (Figure S4B).
These results suggest that fundamentally different mechanisms
regulate the mobilization of phenotypically distinct HPCs,
EPCs, and SPCs.
G-CSF and VEGF Pretreatment Differentially Regulate
the Rate of Egress of Progenitor Cell Subpopulations
from the Bone Marrow in Response
to a CXCR4 Antagonist
To determine whether the differences in circulating numbers of
progenitors cells was due specifically to differences in their rate
of egress out of the bone marrow, we used an in situ perfusion
model of the murine hind limb developed by our group to directly
assess mobilization. In this system, the femoral artery and vein
Figure 2. G-CSF and VEGF Pretreatment
Differentially Regulate Mobilization of
Progenitor Cells in Response to a CXCR4
Antagonist
(A) Overview of procedures set up for identifying
the direct mobilization of progenitor cells from
the femoral bone marrow. Mice were pretreated
with G-CSF, VEGF, or vehicle (PBS) once daily
for 4 days (100 mg/kg i.p.). Twenty-four hours after
the last injection, mice underwent perfusion of the
right hind limb. CXCR4 antagonist (AMD3100
0.1 mM, closed bars) or vehicle (PBS, open bars)
were then infused directly into the femoral artery
for 10 min. The hind limb was then perfused for
a further 50 min to allow collection of (B) CFU-
HPC, (C) CFU-EPC, or (D) CFU-SPC, via the fem-
oral vein. CFU-HPC, CFU-EPC, and CFU-SPC are
shown as total number of colonies collected in
the perfusate. n = 5–8 mice per group. Data
are means ± SEM. *p < 0.05, **p < 0.01, and
***p < 0.001 between selected groups.
are cannulated in situ such that the femur
and tibia bonemarrowareperfused in iso-
lation. Mobilized cells are then collected
via the femoral vein (Martin et al., 2003,
2006). This technique allows direct com-
parisons of the number of cells mobilized
over a defined period of time, without the
complications of progenitor cell traffick-
ing into other tissues, including their
return to thebonemarrow.Micewerepre-
treatedwith vehicle, G-CSF, or VEGF for 4
days. On day 5, the femoral artery was in-
fused for 10 min with either vehicle or the
CXCR4 antagonist, and cells mobilized
were collected over a period of 1 hr (Fig-
ure 2A, Experimental Protocol). When
the CXCR4 antagonist was infused into
vehicle pretreatedmice, HPCs and EPCs,
but not SPCs, were mobilized from the
bone marrow (p < 0.001; Figures 2B–2D). Pretreatment of mice
with G-CSF over 4 days enhanced the basal rate of HPC and
EPC egress from the bone marrow (p < 0.001, Figures 2B and
2C). However, G-CSF pretreatment did not lead to the mobiliza-
tion of SPCs (Figure 2D). As indicated above, G-CSF pretreat-
ment followed by the CXCR4 antagonist led to a synergistic
mobilization of HPCs (p < 0.001, Figure 2B), but not EPCs (Fig-
ure 2C). Furthermore, no SPCsweremobilized (Figure 2D). VEGF
pretreatment resulted in significant EPC mobilization (p < 0.001;
Figure 2C); however, HPCs and SPCs were not mobilized (Fig-
ures 2B and 2D). Furthermore, VEGF pretreatment almost com-
pletely suppressed HPC mobilization induced by infusion of the
CXCR4 antagonist (p < 0.001; Figure 1E; 75% reduction), while
an additive effect was observed for EPC mobilization (p < 0.01;
Figure 2C). Uniquely with this treatment regimen, SPCs were
mobilized (p < 0.001; Figure 2D). These experiments definitively
show that changes in circulating numbers of progenitors are
due to changes in their rate of egress from the bone marrow.64 Cell Stem Cell 4, 62–72, January 9, 2009 ª2009 Elsevier Inc.
Cell Stem Cell
Differential Mobilization of Progenitor SubsetsAcute Administration of Cytokines Does Not Result in
the Differential Mobilization of HPCs, EPCs, and SPCs
in Response to the CXCR4 Antagonist
The selective mobilization of EPCs and SPCs achieved by treat-
ing mice over 4 days with VEGF followed by administration of the
CXCR4 antagonist was not reproduced when mice were treated
acutely with a combination of VEGF and the CXCR4 antagonist.
Infusion of either G-CSF or VEGF directly into the femoral artery
for 10 min and collection up to 60 min mobilized both HPCs and
EPCs (p < 0.001; Figures S5A and S5B). However, acute admin-
istration of VEGF (in contrast to VEGF pretreatment over 4 days)
did not inhibit themobilization of HPCswith a CXCR4 antagonist,
and acute administration of G-CSF did not act synergistically
with the CXCR4 antagonist to mobilize HPCs (Figures S5A and
S5B). Further, neither growth factor, when administered acutely
or in combination with the CXCR4 antagonist, led to mobilization
of SPCs (Figure S5C). This suggested that the ability of G-CSF
and VEGF to promote the differential mobilization of progenitor
cell subsets is dependent on changes to the bone marrow envi-
ronment or the progenitor cell phenotype that occurs over a num-
ber of days.
Figure 3. VEGF Treatment Does Not Alter
the Number of Progenitor Cells Residing in
the Bone Marrow or the Morphology of the
Bone Marrow
Mice were treated with G-CSF, VEGF, or vehicle
(PBS), administered once daily for 4 days
(100 mg/kg i.p.). Twenty-four hours after the last in-
jection, bone marrow was aspirated for the enu-
meration of (A) CFU-HPC bone marrow frequency,
(B) CFU-EPC bone marrow frequency, and (C)
CFU-SPC bone marrow frequency. Femurs from
other mice were fixed in situ and processed for
(D) bone marrow morphology of vehicle and
VEGF-treated mice at 320 and 360 objective.
n = 4–8 per group. Data are mean ± SEM. *p <
0.05 and ***p < 0.001 between selected groups.
VEGF Treatment Does Not Alter
Bone Marrow Morphology
or Progenitor Cell Frequency
Wenext determinedwhether treatment of
mice over 4 days with VEGF or G-CSF
affected the number of progenitor cells
in the bone marrow. The total number of
cells in the femurs of mice treated with
VEGF (1.07 ± 0.11 3 107 cells/femur) or
G-CSF (1.41 ± 0.28 3 107 cells/femur)
was not significantly different compared
to control mice (1.19 ± 0.07 3 107 cells/
femur). Furthermore, no difference was
observed in the frequency of HPCs
(Figure 3A), EPCs (Figure 3B), or SPCs
(Figure 3C) in the bone marrow of
VEGF-treated mice compared to con-
trols. However, G-CSF treatment did
cause a significant reduction in the num-
ber of bone marrow EPCs (p < 0.001,
Figure 3B) and an increase in the number of SPCs (p < 0.05,
Figure 3C).
To determine whether VEGF treatment of mice affected the
gross morphology of the bone marrow, we performed histologi-
cal analysis of bonemarrow inmice treated over 4 dayswith PBS
or VEGF. As shown in Figure 3D, we observed no differences in
the gross morphology, the number of sinusoidal blood vessels,
or endothelial integrity (Figure 3D). Thus, with no gross morpho-
logical changes occurring to the bone marrow of mice treated
with VEGF that might affect cellular egress, we next examined
whether the molecular retention mechanisms had been
disturbed.
VEGF Treatment Does Not Alter the Expression
of CXCR4 on HPCs or EPCs
In mice treated with G-CSF, we observed a significant reduc-
tion in levels of SDF-1a (p < 0.001, Figure 4A) and CXCR4
expression on HPCs (p < 0.05, Figure 4B); however, the ex-
pression of CXCR4 on EPCs was unchanged (Figure 4C), sug-
gesting that G-CSF does not directly effect EPC retention. In
contrast, VEGF treatment did not alter the expression ofCell Stem Cell 4, 62–72, January 9, 2009 ª2009 Elsevier Inc. 65
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over, SDF-1a levels in bone marrow supernatant following
VEGF treatment were not altered (Figure 4A). While the anti-
CXCR4 antibody used here is targeted to the epitope match-
ing the first 63 amino acids starting from the N terminus of
a GST-NCXCR4 fusion protein (Forster et al., 1998), it is noted
that G-CSF will cleave part of this epitope, inhibiting the func-
tion of CXCR4 (Levesque et al., 2003). Thus, reduced antibody
binding indicates either a reduction in the expression of the
functional receptor or an absolute loss of the receptor. Thus,
we can conclude that VEGF treatment does not inhibit the
function of CXCR4 or affect its cell-surface expression. These
data indicate that VEGF treatment does not disrupt the
CXCR4/SDF-1a retention pathway and, therefore, explains
why VEGF alone does not mobilize HPCs from the bone
marrow.
Figure 4. VEGF Treatment Does Not Alter the Ex-
pression of CXCR4 on HPCs or EPCs; However,
VEGF Suppresses Bone-Marrow-Derived HPC
Chemotaxis toward SDF-1a
Mice were treated with G-CSF, VEGF, or vehicle (PBS),
administered once daily for 4 days (100 mg/kg i.p.).
Bone marrow was aspirated on day 5 and harvested
cells were used to determine (A) SDF-1a levels in bone
marrow supernatant as determined by ELISA, (B) percent
of bone marrow LinSca-1+ cells expressing CXCR4, and
(C) percent of bone marrow CD34+ VEGFR2+ cells
expressing CXCR4. Harvested cells were also utilized
in the following chemotaxis assays: (D) number of
HPCs and (E) EPCs undergoing chemotaxis toward
30 nM SDF-1a. Cells taken from bone marrow of mice
treated with G-CSF (closed bars) or vehicle (PBS, open
bars). (F) Number of HPCs and (G) EPCs undergoing
chemotaxis toward 30 nM SDF-1a. Cells taken from
bone marrow of mice treated with VEGF (closed bars) or
vehicle (PBS, open bars). n = 4–8 per group. Data are
mean ± SEM. *p < 0.05 and ***p < 0.001 between selected
groups.
VEGF Treatment Inhibits HPC, but Not
EPC Chemotaxis, toward SDF-1a
Mobilization is dependent on cellular migration
across the bone marrow sinusoidal endothe-
lium. Given that VEGF did not alter CXCR4
expression on HPCs or EPCs (Figures 4B and
4C), we examined the ability of bone-marrow-
derived HPCs and EPCs from G-CSF- or
VEGF-treated mice to undergo chemotaxis
toward SDF-1a in vitro since in PBS-treated
mice, both HPCs and EPCs migrated to SDF-
1a (p < 0.001; Figures 4D–4G). G-CSF treatment
leads to further increased migration of HPCs
and EPCs to SDF-1a (p < 0.001; Figures 4D
and 4E). In contrast, VEGF treatment abolished
the ability of HPCs to migrate to SDF-1a but
had no effect on EPC migration (Figures 4F
and 4G). The suppression of HPC chemotaxis
toward SDF-1a suggested that HPCs from
VEGF-treated mice were refractory to migratory stimuli despite
expressing CXCR4.
VEGF Treatment Does Not Affect the Ability
of Neutrophils to Undergo Chemotaxis
Neutrophils, like progenitor cells, are also retainedwithin the bone
marrowby theCXCR4/SDF-1aaxisand,assuch,canbemobilized
by G-CSF treatment or CXCR4 antagonism (p < 0.001; Figure 5A;
Martin et al., 2003).We, therefore, investigatedwhether VEGFpre-
treatment of mice suppressed neutrophil mobilization as we ob-
served for HPC mobilization (Figures 1B and 2B). As shown in
Figure 5A, VEGF pretreatment profoundly suppressed neutrophil
mobilization in response to the CXCR4 antagonist (p < 0.05, 92%
reduction). This effectwas not seenwhenVEGFwas administered
acutely to mice (Figure 5B). We, therefore, investigated whether
the migratory capacity of neutrophils after VEGF treatment was66 Cell Stem Cell 4, 62–72, January 9, 2009 ª2009 Elsevier Inc.
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tions, neutrophils are rapidly mobilized from the bone marrow by
ELR+ CXC chemokines (e.g., KC), which stimulate neutrophil mi-
gration across the bone marrow sinusoidal endothelium (Martin
et al., 2003;Wengner et al., 2008). Surprisingly, KC-inducedmobi-
lization of neutrophils in vivo was completely abrogated in mice
pretreatedwithVEGF (p<0.001; Figure5C).However, VEGF treat-
ment did not affect either the proportion of Gr-1+ bone marrow
neutrophils expressing CXCR2 (Figure 5D) or the ability of bone
marrow neutrophils to migrate toward KC in vitro (Figure 5E).
Thus,while VEGFpretreatment suppressedbothHPCandneutro-
phil mobilization in vivo, neutrophils, but not HPCs, retained the
ability toundergochemotaxis in vitro, suggesting that the suppres-
sion of HPC chemotaxis was particular to their character as
progenitor cells compared to neutrophils, which are terminally dif-
ferentiated cells. Analysis of bone marrow revealed a significant
reduction in absolute numbers of mature neutrophils (band and
segmented nuclei) following VEGF treatment (Figure 5F). It is un-
clear, however, whether this reduction in the bonemarrow reserve
accounts for the dramatic reduction in neutrophil mobilization.
Figure 5. VEGF Pretreatment Suppresses Neutro-
phil Mobilization, but Does Not Affect Their Ability
to Undergo Chemotaxis
Mice were pretreated with G-CSF, VEGF, or vehicle (PBS),
administered once daily for 4 days (100 mg/kg i.p.).
Twenty-four hours later, these mice underwent perfusion
of the right hind limb. CXCR4 antagonist (AMD3100
0.1 mM, closed bars) or vehicle (PBS, open bars) were
then infused directly into the femoral artery for 10 min.
The hind limb was then perfused for a further 50 min to
allow collection of (A) neutrophils via the femoral vein. In
other perfusion experiments, CXCR4 antagonists or PBS
were infused in addition to VEGF (50 nM), G-CSF
(50 nM), or vehicle (PBS) into the femoral artery of naive
mice for 10min. The hind limbwas again perfused for a fur-
ther 50 min to allow (B) collection of neutrophils. In some
groups of mice pretreated with VEGF over 4 days, KC
(30 mg/kg i.v.) was administered 24 hr after the last injec-
tion of VEGF and (C) circulating neutrophil numbers (deter-
mined by blood smears) were counted 60min after admin-
istration of KC (closed bars) or vehicle (PBS, open bars).
(D) Percent of Gr-1high neutrophils expressing CXCR2
and (E) Neutrophil chemotaxis toward KC (30 nM) of neu-
trophils taken from bone marrow of mice pretreated with
VEGF or vehicle (PBS). (F) leukocyte counts of bone
marrow taken from mice pretreated with VEGF, G-CSF,
or vehicle (PBS). n = 4–8 mice per group. Data are
mean ± SEM. *p < 0.05 and ***p < 0.001 between selected
groups.
VEGF Treatment Stimulates Entry of
HPCs, but Not EPCs, into the Cell Cycle
Activation of HPCs via VEGFR1 is required for
cell survival and cell cycling (Hattori et al.,
2001; Gerber et al., 2002). Since a refractoriness
of HPCs to migrate is a feature of cell cycling
(Bowie et al., 2006; Uchida et al., 1997; Roberts
and Metcalf, 1995), we next tested whether
VEGF treatment ofmice stimulatesHPCprolifer-
ation. Examination of HPC colonies grown from
bone marrow of VEGF-treated mice revealed a
significant increase in both their cellular content and size com-
pared to controls (Figures 6A and 6B), suggesting that VEGF pro-
motes proliferation of CFU-HPC ex vivo. In vivo analysis revealed
that VEGF treatment led to a significant increase in the percent-
age of BM-HPCs (LinSca-1+ cells) in the S/G2/M proliferative
phase of the cell cycle (Figure 6C). In direct contrast, VEGF treat-
ment did not alter the percentage of CD34+VEGFR2+ EPCs in the
S/G2/Mphase of the cell cycle (Figure 6D).Moreover, while VEGF
has thecapacity, as aprimarygrowth factor, to alter the cell-cycle
status of HPCs (Gerber et al., 2002), we show, as previously
described, that G-CSF does not stimulate entry of either HPCs
(Figure 6C) or EPCs (Figure 6D) into the S/G2/M phase of the
cell cycle (McKinstry et al., 1997; Colvin et al., 2007). However,
as shown by others, G-CSF does promote expansion and differ-
entiation of granulocytes, as evident by the increased numbers of
neutrophils in thebonemarrow (Figure 5F) (McKinstry et al., 1997;
Lord et al., 1989).
HPCs are known to express VEGFR1 (Figure S1); therefore, we
next investigated whether the effect of VEGF in stimulating the
entry of HPCs into the cell cycle in vivo was mediated via thisCell Stem Cell 4, 62–72, January 9, 2009 ª2009 Elsevier Inc. 67
Cell Stem Cell
Differential Mobilization of Progenitor SubsetsFigure 6. VEGF Pretreatment, Acting via VEGFR1, Enhances HPC Cell Cycling Compared to EPCs
(A) Number of cells per colony and (B) mean colony area of CFU-HPC grown for 12 days in methocult. Cells were taken from bone marrow of mice treated (once
daily for 4 days) with G-CSF, VEGF, or vehicle (PBS) (100 mg/kg i.p.). Representative histograms of PI stain of DNA content for LinSca-1+ HPCs, (Ci) PBS-treated,
(Cii) VEGF-treated, (Ciii) G-CSF-treated, and (Civ) percent of LinSca-1+ HPCs residing in S/G2/M phase of the cell cycle. Representative histograms of PI stain of
DNA content for CD34+VEGFR2+ EPCs, (Di) PBS-treated, (Dii) VEGF-treated, (Diii) G-CSF-treated, and (Div) percent of CD34+VEGFR2+ EPCs residing in S/G2/M
phase of the cell cycle. In another experiment, mice were treated with anti-VEGFR1 antibody (2.5 mg/kg) or control IgG on days 1 and 3, 30 min before VEGF
administration. Representative histograms of PI stain of DNA content for LinSca-1+ HPCs, (Ei) PBS-treated, (Eii) VEGF-treated + anti-IgG, (Eiii) VEGF-treated +
anti-VEGFR1 antibody, and (Eiv) percent of LinSca-1+ HPCs residing in S/G2/M phase of the cell cycle. n = 4–7 per group. Data are mean ± SEM. *p < 0.05 and
**p < 0.01 between selected groups.receptor. We show here that in vivo administration of an antibody
directed against VEGFR1 completely suppressed the VEGF-
stimulated entry of HPCs into the cell cycle (Figure 6E).
VEGFR1 Antagonism Reverses VEGF-Induced
Suppression of HPC Mobilization in Response
to a CXCR4 Antagonist
Administration of a VEGFR1 blockingmAb to VEGF-treatedmice
completely restored the ability of the CXCR4 antagonist to mobi-68 Cell Stem Cell 4, 62–72, January 9, 2009 ª2009 Elsevier Inc.lize HPCs from the bone marrow (p < 0.001; Figure 7A). In
contrast, anti-VEGFR1 antibody administration did not affect
VEGF-induced mobilization of EPCs (Figure 7B). These data
indicate that VEGF acting via VEGFR1 stimulates the entry of
HPCs into the cell cycle and blocks their mobilization from the
bone marrow, while effects of VEGF on VEGFR2 stimulate the
mobilization of EPCs. Hence the differential effects of VEGF in
regulating HPC and EPC mobilization are due to actions via
distinct receptors.
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We show here that the mobilization of progenitor cell subsets is
differentially regulated by growth factors that affect their reten-
tion and cell-cycle status. Specifically, we show that while max-
imal mobilization of HPCs occurs when the CXCR4 antagonist is
administered to mice pretreated with G-CSF, under these condi-
tions, neutrophil mobilization is also maximal, while EPC mobili-
zation is submaximal and SPCs are not mobilized. In contrast,
when mice are pretreated with VEGF, the acute administration
of a CXCR4 antagonist stimulates mobilization of EPCs and
SPCs while suppressing HPC and neutrophil mobilization. As
such, the profile of progenitor cells and leukocytes in the blood
changes dramatically depending on the treatment protocol.
The retention of HPCs and mature neutrophils within the bone
marrow is dependent on the SDF-1a/CXCR4 chemokine axis.
Thus, mechanisms that disrupt this axis promote the egress of
HPCs and neutrophils (Martin et al., 2003; Levesque et al.,
Figure 7. VEGFR1 Blockade Reverses VEGF-Induced
Suppression of HPC Mobilization in Response to
a CXCR4 Antagonist
Mice were pretreated with VEGF, or vehicle (PBS) once daily
for 4 days (100 mg/kg i.p.). Mice pretreated with VEGF were
additionally administered control IgG or anti-VEGFR1 anti-
body (2.5 mg/kg) on days 1 and 3, 30 min before VEGF admin-
istration. Twenty-four hours after the last injection, mice were
administered a CXCR4 antagonist (AMD3100 5 mg/kg i.p,
closed bars) or vehicle (PBS, open bars). Sixty minutes later,
blood was taken for analysis of circulating (A) CFU-HPC and
(B) CFU-EPC. (C) Representation of the divergent roles of
G-CSF and VEGF treatment on HPC and EPC status in bone
marrow. n = 4 per group. Data are mean ± SEM. *p < 0.05
and ***p < 0.001 between selected groups.
2003). Consistent with previous reports, we show
here that G-CSF mobilizes both neutrophils and
HPCs by reducing their expression of CXCR4 and
decreasing levels of SDF-1a within the bone mar-
row (Levesque et al., 2003; Wengner et al., 2008).
In contrast, G-CSF alone mobilized only modest
numbers of EPCs, and no additive or synergistic
effects were observed when mice pretreated with
G-CSF were administered the CXCR4 antagonist.
There are no reports that EPCs express G-CSF re-
ceptors. Further, in this study G-CSF had no effect
on the expression of CXCR4 by EPCs. These data
suggest that G-CSF does not have a direct effect
on EPCs, which may explain why mobilization of
EPCs with the CXCR4 antagonist could not be
enhanced by pretreatment of mice with G-CSF.
Unexpectedly, pretreatment of mice with VEGF
suppressed the mobilization of both neutrophils
and HPCs in response to the CXCR4 antagonist.
This was not due to a change in CXCR4 expression
by these cells. HPCs mobilized by G-CSF have
been found to be exclusively in the Go/G1 phase
of cell cycle, whereas HPCs remaining in the bone
marrow are actively cycling (Bowie et al., 2006;
Uchida et al., 1997; Roberts and Metcalf, 1995). This may be
explained by the fact that proliferating HPCs cannot migrate,
a necessary step in their mobilization from the bone marrow.
Here we show that the exogenous administration of VEGF to
naive mice stimulates the entry of HPCs into the S/G2/M phase
of the cell cycle in vivo and thereby severely impairs the migra-
tory capacity of these cells in vitro. Furthermore, as a conse-
quence of their inability to migrate, the mobilization of HPCs by
the CXCR4 antagonist is completely abrogated in mice treated
with VEGF. It has previously been proposed that there are two
pools of HPCs, a quiescent dormant reserve of HPCs residing
in the endosteal niche that accounts for approximately one-third
of the HPCs and a ‘‘mobilizable’’ pool of HPCs that have the
potential to proliferate residing in the vascular niche adjacent
to the sinsusoidal endothelium (Wilson et al., 2007). We propose
that in stimulating HPCs in the vascular niche to enter the cell
cycle, VEGF has a profound effect on HPC mobilization (Wilson
et al., 2007).Cell Stem Cell 4, 62–72, January 9, 2009 ª2009 Elsevier Inc. 69
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suppressed mice with a blocking mAb to VEGFR1 reduces cell
cycling of HPCs and the survival of HSCs following engraftment
(Gerber et al., 2002 Hattori et al., 2002), suggesting that endoge-
nous VEGFacting via VEGFR1 regulates the proliferation/survival
of HPCs/HSCs in the bone marrow (Gerber et al., 2002). In this
study,weshow that that selectiveblockadeof VEGFR1abolishes
the ability of exogenous VEGF to stimulate HPC entry into the
cell cycle in vivo and restores the ability of CXCR4 antagonists
to mobilize HPCs from the bone marrow.
Interestingly, the mobilization of neutrophils in response to
both the CXCR4 antagonist and the chemokine, KC, was dra-
matically inhibited in mice pretreated with VEGF. This is not
due to an effect on cell proliferation, as these are terminally dif-
ferentiated cells. Indeed, neutrophils harvested from the bone
marrow of VEGF-treated mice migrated normally in response
to chemokines. This suggests that VEGF may affect egress of
mature cells from the bone marrow by other, as yet unidentified
mechanisms.
VEGF stimulates the migration and promotes survival of endo-
thelial cells via signals emanating from VEGFR2 (Gerber et al.,
1998). Interestingly, we observed that VEGF treatment of mice
did not stimulate the proliferation of VEGFR2+/CD34+ EPCs,
andassuch,EPCs in thebonemarrowof thesemice retained their
ability to migrate toward chemokines in vitro and to be mobilized
in response to CXCR4 antagonists in vivo. The differential effects
of VEGF in regulatingHPCandEPCmobilization aremediated via
distinct receptors, VEGFR1 on HPCs and VEGFR2 on EPCs. The
ability ofVEGF todifferentiallypromote thecell cyclingofHPCsas
compared to EPCs explains why EPCs can be selectively mobi-
lized by the CXCR4 antagonist in mice treated over 4 days with
VEGF. Consistent with this data is the finding that acute adminis-
tration of VEGF alone or in combination with the CXCR4 antago-
nist did not selectively mobilize EPCs from the bone marrow.
Mechanistic differences between acute and chronic VEGF expo-
sure areunknown;however, acuteadministrationof highdosesof
VEGF, delivered by adenovirus, is associated with capillary leak-
inesswhichmay facilitate the escape ofmyeloid cells, HPCs, and
EPCs from the BM (Moore et al., 2001; Hattori et al., 2001).
The G-CSF treatment protocol used here has been evaluated
to promote cardiac regeneration in patients with MI (Orlic et al.,
2001; Kocker et al., 2001; Zohlnho¨fer et al., 2006; Ince et al.,
2005; Ripa et al., 2006; Ellis et al., 2006; Hill et al., 2005). These
trials have been disappointing, with only 1 out of 5 trials showing
any significant clinical benefit (Zohlnho¨fer et al., 2006; Ince et al.,
2005; Ripa et al., 2006; Ellis et al., 2006; Hill et al., 2005). As we
reveal here, such limited clinical success might be because
G-CSF administration is not a particularly efficacious regimen
for mobilizing EPCs or SPCs, whichmay be important for cardiac
regeneration. Indeed, we have shown that G-CSF treatment
actually decreases the number of EPCs in bonemarrow, thus de-
pleting the available reservoir for tissue recruitment and revascu-
larization. In this study, we have identified a treatment protocol
that selectively mobilizes EPCs and SPCs, but not HPCs or
neutrophils, from thebonemarrow. Future studieswill investigate
the therapeutic efficacy of this mobilizing regime for cardiac
regeneration following myocardial infarction.
Taken together, the results presented here indicate that differ-
ent factors and molecular mechanisms regulate the mobilization70 Cell Stem Cell 4, 62–72, January 9, 2009 ª2009 Elsevier Inc.of discrete populations of progenitor cells from the bonemarrow.
This has far-reaching implications for our understandingofmech-
anisms regulating the selective recruitment of different popula-
tions of progenitor cells in disease and the development of
therapeutic strategies to mobilize specific subpopulations for
regenerative medicine.
EXPERIMENTAL PROCEDURES
Pretreatment with G-CSF or VEGF
Eight- to ten-week old female BALB/c mice (Harlan, Oxford, UK) were admin-
istered VEGF (2.5 mg/mouse i.p.), G-CSF (2.5 mg/mouse i.p.), or vehicle on 4
consecutive days. Twenty-four hours after the last injection, mice were admin-
istered a CXCR4 antagonist (AMD3100, 5 mg/kg i.p), KC (30 mg/kg i.v.), or
vehicle and blood was collected via cardiac puncture 60 min later for enumer-
ation of circulating leukocyte, HPC, EPC, and SPC levels. In other experi-
ments, mice pretreated with G-CSF or VEGF were used for in situ perfusion
of the mouse hind limb as explained below. All studies were carried out under
the United Kingdom’s Animals (Scientific Procedures) Act of 1986 and local
ethical approval from Imperial College, London.
Administration of Anti-VEGFR1 Antibody
Mice were administered anti-VEGFR1 or control IgG (2.5 mg/kg i.p.) (Ohki
et al., 2005) 30 min before VEGF administration on days 1 and 3 of the 4 day
VEGF treatment protocol.
In Situ Perfusion of Mouse Hind Limb
On day 5 following pretreatment of growth factors, mice were anaesthetized,
and the femoral artery and vein were exposed. The hind limb was isolated by
occlusion of the external iliac artery, superficial epigastric branch, and muscu-
lar branch. Polyethylene cannulae (Portex, London, UK) were immediately
inserted into the femoral artery and vein as previously described (Martin
et al., 2003, 2006; Wengner et al., 2008). Perfusion buffer was infused via
the arterial cannula and removed from the venous cannula using a Minipuls
peristaltic pump (Anachem, Luton, UK). The hind limb was perfused for an ini-
tial 2 min to remove remaining blood from the vasculature and then perfused
for a further 60 min with vehicle alone or the CXCR4 antagonist (AMD3100,
0.1 mM), infused over the first 10 min using an infusion/withdrawal pump (Har-
vard Instruments, UK). In some studies, the effects of acute administration of
G-CSF or VEGF on HPC, EPC, and SPC mobilization were examined. G-CSF
or VEGF (50 nM) were added to the perfusion buffer for an initial 10 min.
Analysis of Mobilized Cells from the Bone Marrow
in Blood and Perfusate
Theperfusatewas centrifuged and resuspended inDMEM+20%FBS. In some
experiments, citrated blood was obtained via cardiac bleed and lysed for red
blood cells. Bonemarrow, perfusate cytospins, andblood smearswere stained
using DiffQuik for the enumeration of mononuclear cells, eosinophils, and neu-
trophils. Bone marrow, perfusate, and lysed blood were then used for assays
outlined below to enumerate HPCs (CFU-HPC), EPCs (CFU-EPC), and SPCs
(CFU-F).
CFU-HPC Assay
5 3 104 cells were added to Methocult medium (StemCell Technologies, Inc.)
and were incubated for 11 days before quantification. Further characteristics
of CFU-HPC colonies were obtained on day 12: namely, the mean number
of cells in each colony and the mean colony area. The mean colony area
(mm2) was determined by image analysis using Scion Image analysis program
(NIH). The cell number was determined by diluting colonies grown inMethocult
into DMEM and aspirating the colonies into a single cell suspension before ob-
taining a cell count. Cells taken from HPC colonies and immunostained
showed CD115-, CD34-, CD45-, and VEGFR1-positive cells, but were nega-
tive for VEGFR2, VE-Cadherin, and von Willebrand Factor (vWF) (Figure S1).
CFU-EPC Assay
53 105 cells were added to EPC colony media (EGM-2 basal media + supple-
ments; additional VEGF: 60 mg/l and 16% FBS) on fibronectin-coated plates.
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Differential Mobilization of Progenitor SubsetsDishes were incubated for 7 days before media was changed and incubated
for a further 14 days before the enumeration of EPC colonies (CFU-EPC).
These ‘‘late outgrowth’’ EPC colonies exhibited a cobblestone morphology
and by immunohistochemical analysis (protocol can be found in the Supple-
mental Experimental Procedures) expressed CD34, VEGFR2, VE-Cadherin,
and vWF (Figure S1) stained positively with GS-lectin and were able to uptake
acetyl-LDL (Figure S2A), as reported by others (Nolan et al., 2007; Yoder et al.,
2007). Importantly, ‘‘late outgrowth’’ CFU-EPC did not express CD115, CD14,
or CD45 (Figure S1) and are, therefore, not of amonocyte-macrophage lineage
(Yoder et al., 2007). Moreover, CFU-EPCwere able to form tubules in an in vitro
EC Matrix angiogenesis assay (see the Supplemental Experimental Proce-
dures), whereby complete mesh-like structures formed after 18 hr in culture
(Figures S2B–S2D).
CFU-SPC Assay
5 3 105 cells were added to Mesencult media, including supplements (Stem-
Cell Technologies, Inc.). Dishes were incubated for 7 days before media was
changed and incubated for a further 14 days before the enumeration of SPC
colonies (CFU-F). Plastic adherent bone-marrow-derived SPCs were shown
to express CD29 and CD105 and were negative for CD45 and CD34 (Fig-
ure S4A) as demonstrated in previous studies on SPCs (Phinney et al., 1999;
Pittenger et al., 1999). Furthermore, expanded SPC colonies were assessed
for their ability to differentiate into other cell types (Supplemental Experimental
Procedures) and were capable of mesenchymal trilineage differentiation into
adipocytes (Figure S3C), osteoblasts (Figure S3D), and chondrocytes (Fig-
ure S3E) These progenitor cells exhibit all the characteristics of murinemesen-
chymal stem cells (Pittenger et al., 1999).
Flow Cytometry Analysis of Chemokine Receptor Expression
on Cells Residing in Bone Marrow
For flowcytometric analysis, cellswere resuspended in FACSbuffer. To identify
neutrophils in the bone marrow, surface expression of the granulocyte marker
Ly-6G/Ly6C (Gr-1) was determined. Neutrophils were identified as Gr-1high-
positive cells with a characteristic high side scatter profile. HPCswere selected
as being negative for lineage (Lin) markers CD3e, CD11b, CD45R, Ly-76, and
Gr-1 and positive for Sca-1 (LinSca-1+ cells) (Gerber et al., 2002; Uchida et al.,
1997). EPCs were selected as being positive for both CD34 and VEGFR2
(CD34+VEGFR2+ cells) (Asahara et al., 1997; Yoon et al., 2005). Furthermore,
neutrophils were stained for the surface expression of CXCR2, while
LinSca-1+ cells andCD34+VEGFR2+ cells were stained for the cell surface ex-
pression of CXCR4. Samples were then washed and quantified on a FACSAria
cell sorter (BD Biosciences, Oxford, United Kingdom) and analyzed using
FACSDiva software.
PI Staining to Determine Cell-Cycle Status
LinSca-1+ cells and CD34+ VEGFR2+ cells were analyzed to determine their
cell-cycling status using apropidium iodide (PI) stain. Unfixed cellswere initially
stained as explained above to identify their cell type before the addition of 50 ml
PI (100mg/ml), and 50ml RNase (100 mg/ml) was added tominimize PI binding to
RNA. Five minutes before flow cytometric analysis, 50 ml of 0.1% Triton X (in
saline) was added to sample to permeabilize the cell membrane and allow
DNA binding. A dot plot of PI width (PI-A) against PI area (PI-A) was recorded.
Aggregates of cells were detected as cells having a larger PI-W profile and
were not included in the gate. A PI-A histogram of the gated cells showed the
first peak to represent cells in G0/G1, the second peak cells in G2/M, and the
in-between area S phase cells.
In Vitro Chemotaxis Assays of Neutrophils, HPCs, and EPCs
Bonemarrow-derived neutrophils were tested for migration toward KC (30 nM)
using 3 mm pore-sized transwell chemotaxis plates as previously described
(Wengner et al., 2008). To measure HPC and EPC migration toward SDF-1a,
murine bone marrow cells (2 3 106 cells) were placed in the upper chamber
of transwell inserts (5 mm pore size, Corning). These, in turn, were placed in
individual wells of a 24-well cell culture plate with 30 nMSDF-1a added. Cham-
bers were incubated for 4 hr at 37C, and migrated cells were then placed in
methocult or EPC colony media as described above for the enumeration of
CFU-HPC and CFU-EPC.Statistical Analysis
Data are expressed as mean ± SEM. In vivo mobilization data and in vitro
chemotaxis data were analyzed using two-way analysis of variance (ANOVA),
followed by Bonferroni multiple-comparisons test. Flow cytometry data of PI
stain were analyzed using one-way ANOVA, followed by Bonferroni multiple-
comparisons test. Flow cytometry data of chemokine receptor expression
were analyzed using a Student’s t test. All analyses were conducted using
the GraphPad Prism statistical package (version 4.0; Graph Pad, San Diego,
CA). p values less than 0.05 were considered significant.
SUPPLEMENTAL DATA
The Supplemental Data include Supplemental Experimental Procedures, Sup-
plemental References, and five figures and can be found with this article online
at http://www.cell.com/cell-stem-cell/supplemental/S1934-5909(08)00571-7.
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